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Objective: This study weighed the cost and beneﬁt of thoracic endovascular aortic repair (TEVAR) vs open repair (OR) in
the treatment of an acute complicated type B aortic dissection by (TBAD) estimating the cost-effectiveness to determine
an optimal treatment strategy based on the best currently available evidence.
Methods: A cost-utility analysis from the perspective of the health system payer was performed using a decision analytic
model. Within this model, the 1-year survival, quality-adjusted life-years (QALYs), and costs for a hypothetical cohort of
patients with an acute complicated TBAD managed with TEVAR or OR were evaluated. Clinical effectiveness data, cost
data, and transitional probabilities of different health states were derived from previously published high-quality studies
or meta-analyses. Probabilistic sensitivity analyses were performed on uncertain model parameters.
Results: The base-case analysis showed, in terms of QALYs, that OR appeared to be more expensive (incremental cost of
V17,252.60) and less effective (L0.19 QALYs) compared with TEVAR; hence, in terms of the incremental cost-
effectiveness ratio, OR was dominated by TEVAR. As a result, the incremental cost-effectiveness ratio (ie, the cost per
life-year saved) was not calculated. The average cost-effectiveness ratio of TEVAR and OR per QALY gained was
V56,316.79 and V108,421.91, respectively. In probabilistic sensitivity analyses, TEVAR was economically dominant in
100% of cases. The probability that TEVAR was economically attractive at a willingness-to-pay threshold of V50,000/
QALY gained was 100%.
Conclusions: The present results suggest that TEVAR yielded more QALYs and was associated with lower 1-year costs
compared with OR in patients with an acute complicated TBAD. As a result, from the cost-effectiveness point of
view, TEVAR is the dominant therapy over OR for this disease under the predeﬁned conditions. (J Vasc Surg
2014;59:1247-55.)Acute aortic dissection is the most common aortic
emergency and affects about three to four per 100,000 per-
sons per year.1 Approximately 30% to 42% of the acute type
B aortic dissections (aTBADs) are complicated, and 20% to
30% of patients die before hospital admission.2,3
Open repair (OR) using prosthetic graft interposition is
the conventional treatment for acute complicated TBADs.
Despite remarkably improved operative techniques and
improved perioperative care, the results of OR of the
aTBADs are reported with contemporary mortality rates
of 15% to 30% and even >50% in complicated cases under
emergency conditions.4,5 Another devastating complica-
tion of OR is ischemic spinal cord injury, with paraplegia
rates up to 30%.6
Interventions using thoracic endovascular aortic repair
(TEVAR) have added a strong alternative and new dimen-
sion to the surgical management of aortic dissection, and
recently, the paradigm of treatment of acute complicated
distal dissections has shifted in favor of TEVAR over OR.the Department of Vascular and Endovascular Surgery, University
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have been discussed controversially. The currently available
literature is sparse and complicated by heterogeneous clin-
ical deﬁnitions and therapeutic treatments, and information
on late outcome is scant. To date, we still lack level 1 evi-
dence in support of TEVAR for TBADs because no ran-
domized trials of TEVAR vs OR for aTBADs have been
performed with substantial follow-up. Thus, management
recommendations for aTBADs are mostly derived from un-
controlled retrospective cohorts, case series, registry data,
or expert opinions and are not yet ﬁrmly settled.
In a recent meta-analysis, we showed a signiﬁcant
reduction in perioperative mortality and paraplegia rates
with TEVAR compared with OR.7 In TEVAR, however,
the reintervention rates and the initial device-associated
costs have to be considered. The aim of the present study
was to examine the hypothesis that compared with OR,
TEVAR may be a more cost-effective therapeutic option
for the management of acute complicated TBADs.
METHODS
The analysis was undertaken from a health care system
payer perspective, considering the related total direct med-
ical costs of care for the ﬁrst year. Loss of productivity (in-
direct costs) or costs >1 year of follow-up were not
included in the present study. Costs and health outcomes
in quality-adjusted life-years (QALYs) were assessed and
combined into an incremental cost-effectiveness ratio
(ICER), which should be interpreted as the cost needed
to produce an additional QALY.1247
Table I. Transitional probabilities based on previous meta-analysis and literature search
Final outcome
OR TEVAR converted to OR TEVAR
References
Literature path
probabilities
Plausible
range
Literature path
probabilities
Plausible
range
Literature path
probabilities
Plausible
range
30-day mortalitya 0.299 0.2-0.4 0.026 0.01-0.05 0.115 0.085-0.145 7,9-28
Paraplegia 0.299 0.249-0.349 0.0013 0.001-0.0016 0.049 0.029-0.069 7,10-28
Death 0.0008 . 0.0 . 0.082 0.052-0.112 27-29
Stroke 0.08 0.06-0.1 0.004 0.003-0.005 0.063 0.043-0.083 7,27,28
Death . . . . 0.082 0.0662-0.102 7,27,28
Renal failure 0.098 0.078-0.118 0.0029 0.0019-0.0039 0.069 0.049-0.089 7,12-15,17-21,23-28
Death 0.0086 . 0.0002 . 0.082 0.062-0.102 30
LOS, days
ICU 10 . 10 . 6 . 11,19-23,26,31
Ward 9 . 9 . 7 . 19-23,26,31,32
Ventilatory days 7 . 7 . 2 . 14,22,26
Late endoleak . . . . 0.18 0.15-0.21 7,27,28
Intervention . . . . 0.113 0.083-0.143 7,27,28
Endoleak . . . . 0.2319 0.2019-0.2619 7,27,28
Intervention . . . . 0.2 0.1-0.3 7,27,28
EV, Endovascular repair; ICU, intensive care unit; LOS, length of stay; OR, open repair; TEVAR, thoracic endovascular aortic repair.
aDeﬁned as nonrespiratory, nonparaplegia, nonrenal deaths.
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cal procedure were obtained from previously published data
describing the utilization of health services after TEVAR or
OR for TBADs. Costs and health outcomeswere discounted
at 3% per year, consistent with current guidelines.8 Costs
were based on 2012 prices and, when necessary, were
adjusted by means of the consumer price index for health
and personal care and converted to euros (V). In all cases,
the probability for each outcome was multiplied by the
cost associated for each outcome to give the expected cost
for OR and TEVAR. Cost associated with intensive care
unit length of stay (LOS) and total hospital LOS was then
added to each outcome to arrive at the ﬁnal cost.
The costs and clinical outcomes were modelled by us-
ing a Monte Carlo process. A 1-year time horizon was
adopted to capture all relevant costs and the beneﬁts.
Data. In the present analysis, we focused on those pri-
mary outcomes that were the most serious and those that
resulted in the greatest resource utilization, namely: mor-
tality, paraplegia/paraparesis rate, renal failure, stroke, con-
version to OR, endoleak rate, intensive care unit LOS, and
hospital LOS. We assumed that the remaining outcomes
would be similar in both treatment groups. Especially for
TEVAR, the additional outcomes of endoleak and conver-
sion to OR were analyzed. These outcome data were
mainly extracted from our previously published meta-
analysis on TEVAR for acute complicated TBADs.7 De-
tails of the underlying search criteria, patient selection
criteria, statistical analysis, and sensitivity analysis of the
meta-analysis are available elsewhere.7 Because we used the
data from only a few studies besides those included in the
previously published meta-analysis7 for the baseline anal-
ysis, we took care to ensure that the ranges for the sensi-
tivity analysis included data from other related studies
(Table I). In addition, we ensured that the clinically plau-
sible ranges corresponded with the target population andinterventions that were modelled. To incorporate the re-
sults in the present decision-analytical model, all outcomes
were pooled by meta-analytical means, and the weighted
data of each outcome were used for the present analysis.
The baseline variables and ranges used in sensitivity analysis
are summarized in Tables I-III.
A literature review was undertaken to obtain estimates
of costs, utilities, and health-related quality of life, respec-
tively (Tables I-III). Utility scores were quoted from the
published literature. We used published population-based
utilities, representing time trade-off or standard-gamble
techniques.
Two studies were identiﬁed reporting utilities for post-
stroke states.40,41 Both studies showed that utilities in pa-
tients who had a nondisabling stroke were no lower than
those in patients who had not had a stroke. Therefore,
no decrement in utility was assumed for patients in this
state. For patients who had a disabling stroke, the mean
utility was 0.5. Because the mean utility of the general pop-
ulation is <1 (full health),42 this corresponded to a decre-
ment in the quality-adjustment weight of 0.35.
Decision-analytical model. An observational decision-
analytical model was constructed for the use of resources
and the effectiveness of both treatment strategies on the
basis of a previously published model by Tong et al33 at the
London Health Sciences Center. In the present study, the
distribution type used for different variables was inﬂuenced
by the availability of information in the relevant source
studies. When the information required to generate an
appropriate distribution was not available, we used triangular
distribution. The following hypotheses were made in
developing the model and conducting the analysis:
1. Patients with acute complicated TBADs undergo
TEVAR or OR. Complicated TBADs were character-
ized by thoracic aortic rupture, shock, malperfusion
Table II. Unit costs (follow-up costs limited to 1 year) based on literature search
Resource item
OR TEVAR converted to OR TEVAR
References
Unit costs
(V) Range (V)
Unit costs
(V) Range (V)
Unit costs
(V) Range (V)
30-day mortality 18,051 14,051-22,051 26,051 20,051-32,051 20,030 15,030-25,030 33,34
No acute
complication/
uneventful
recovery
18,177.2 10,177.2-26,177.2 26,177.2 20,177.2-32,177.2 20,156.2 16,156.2-24,156.2 33,34
Paraplegia 142,505.49 12,0505.49-
16,4505.49
15,0505.49 110,505.49-
190,505.49
. . 33-35
Stroke 142,505.49 120,505.49-
164,505.49
15,0505.49 110,505.49-
190,505.49
. . 33-35
Renal failure 155,132.34 110,132.34-
200,132.34
16,3132.34 120,132.34-
203,132.34
. . 33,34
Late endoleak
Intervention . . . . 25,566.13 20,566.13-30,566.13 33,34
No intervention . . . . 20,424.99 16,424.99-24,424.99 33,34
Paraplegia
Survive þ
rehabilitation
. . . . 144,484.49 104,484.49-184,484.49 33-35
Death . . . . 39,884.49 34,884.49-44,884.49 33-35
Early endoleak
Intervention . . . . 25,481.13 20,481.13-30,481.13 33,34
No intervention . . . . 20,339.99 15,339.99-25,339.99 33,34
Stroke
Survive þ
recovery
. . . . 39,884.49 32,884.49-46,884.49 33-35
Death . . . . 39,884.49 32,884.49-46,884.49 33-35
Renal failure
Survive þ
recovery
. . . . 157,111.34 117,111.34-197,111.34 33,34
Death . . . . 52,511.34 45,511.34-60,511.34 33,34
OR, Open repair; TEVAR, thoracic endovascular aortic repair.
Table III. Utilities based on literature search
Resource item
OR þ TEVAR converted
to OR TEVAR
ReferencesUtility Range Utility Range
30-day mortality 0 0 0 0 36-39
No acute complication/uneventful recovery 0.83 0.78-0.88 0.93 0.89-0.97 36-39
Paraplegia 0.6 0.5-0.7 . . 36-39
Stroke 0.46 0.3-0.65 . . 10,11
Renal failure 0.68 0.6-0.8 . . 36-39
Late endoleak
Intervention . . 0.83 0.78-0.88 36-39
No intervention . . 0.83 0.78-0.88 36-39
Paraplegia: survive þ rehabilitation . . 0.6 0.5-0.7 36-39
Early endoleak
Intervention . . 0.83 0.78-0.88 36-39
No intervention . . 0.83 0.78-0.88 36-39
Stroke: survive þ recovery . . 0.46 0.3-0.65 10,11
Renal failure: survive þ recovery . . 0.68 0.6-0.8
OR, Open repair; TEVAR, thoracic endovascular aortic repair.
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lower extremities), intractable hypertension and
pain, or rapid expansion in the distal arch or prox-
imal descending aorta with a total aortic diameter
of $4.5 cm.2. Analysis was done based on intention to treat (ie,
cost associated with conversion to OR counted to-
ward the cost of the TEVAR cohort).
3. Eighty percent of patients with renal failure mortality
would also die of respiratory failure.
Table IV. Incremental cost-effectiveness after 1 year in base-case analysis
Strategy Cost (V) Incremental cost (V) Effectiveness Incremental effectiveness Cost/effectiveness (V) ICER
TEVAR 41,288.59 0.73 56,316.79
OR 58,541.18 17,252.60 0.54 0.19 108,421.91 (dominated by TEVAR)
ICER, Incremental cost-effectiveness ratio; OR, open repair; TEVAR, thoracic endovascular aortic repair.
Fig 1. Sensitivity analysis on willingness-to-pay (WTP). The
preferred treatment in net health beneﬁt is independent of the
WYP threshold value of V50,000 for the thoracic endovascular
aortic repair (TEVAR) option. OR, Open repair.
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require intervention.
5. Patients with endoleak would have a 5% mortality
rate.
6. In the base-case analysis, TEVAR patients in follow-
up would undergo a computed tomography (CT)
scan at 1 month and then every 6 months after to
ensure that no endoleak had developed and that no
endograft migration had taken place.
7. In the base-case analysis, patients in the OR group
would not routinely receive postoperative CT
imaging.
Cost-effectiveness analysis. The time horizon of the
analysis was 1 year. The willingness-to-pay (WTP)
threshold was V50,000. As a result, the intervention was
considered cost-effective if the ICER was <V50,000 per
QALY. End points of this simulation model were the cost-
effectiveness ratios, the ICER, and the net health beneﬁt of
the two treatment options. The effectiveness of each
treatment option was quantiﬁed by QALYs. The type of
dominance of the comparative probability distribution was
analyzed graphically. Cost drivers (variables with the major
input to the costs) were identiﬁed, and results are presented
by means of a tornado diagram. We performed a base-case
analysis and varied all variables over a broad range of
reasonable hypotheses in multiple one-way and two-way
sensitivity analyses to deal with structural uncertainties
within the model and patient-related and treatment-related
variables. Noncost data were varied systematically in the
clinically plausible ranges, and cost data were varied by up
to 50% in each direction in the sensitivity analysis.
In the probabilistic analysis, a second-order Monte
Carlo simulation with all model parameters >10,000 itera-
tions was used to propagate the uncertainty in single-model
inputs through the model so that the uncertainty in the
cost-effectiveness results indicated the uncertainty in the
decision to implement a treatment strategy rather than
the uncertainty surrounding single-model inputs. The re-
sults are presented as scatter plots of the ICER. In addition,
sensitivity analysis included worst-case and best-case sce-
nario analyses.
The decision analysis model was programmed and
analyzed using TreeAge Pro 2009 software (TreeAge Soft-
ware Inc, Williamstown, Mass).
RESULTS
The rationales for the assumptions in our model are
listed in Tables I-III. The relevant costs and adjustment
rates for estimates of missing costs are presented inTable II. Each patient’s costs were calculated using these
assumptions, were compared with actual costs, and were
determined to be comparable.
A literature review revealed one study with a detailed
analysis of the utilization of health services after spinal
cord injury in Alberta and the average costs for the ﬁrst
year.35 The total 1-year cost for each patient represents
the sum of the patient’s total hospital cost, the total
follow-up cost, and additional costs such as rehabilitation
for paraplegic patients or home care nursing visits.
Baseline conditions. In the base-case analysis, in
terms of QALYs, OR appeared to be more expensive (in-
cremental cost of V17,252.60) and less effective (0.19
QALYs) compared with TEVAR; hence, in terms of the
ICER, OR was dominated by TEVAR. As a result, we did
not calculate the ICER (ie, the cost per life-year saved).
The average cost-effectiveness ratio of TEVAR and OR
per QALY gained was V56,316.79 and V108,421.91,
respectively (Table IV).
Considering the net health beneﬁt (Fig 1), the
preferred treatment was TEVAR compared with OR, inde-
pendently on the threshold value of WTP (of V50,000).
One-way sensitivity analysis. The outcome of the
model remained robust, and TEVAR maintained its cost-
effectiveness advantage over OR within broad predeﬁned
ranges for different WTP thresholds, costs, and probabili-
ties; namely, uneventful course, paraplegia, stroke, renal
Table V. Dominance report of one-way sensitivity analysis
Therapeutic option Parameter ICER
OR þ TEVAR converted to OR Costs of no acute complication OR dominated by TEVAR
Costs of paraplegia
Costs of stroke
Costs of renal failure
TEVAR Costs of no acute complication or uneventful recovery OR dominated by TEVAR
Costs of paraplegia-survive
Costs of stroke-survive
Costs of renal failure-survive
OR þ TEVAR converted to OR þ TEVAR Probability of 30-day death OR dominated by TEVAR
Probability of paraplegia
Probability of stroke
Probability of renal failure
ICER, Incremental cost-effectiveness ratio; OR, open repair; TEVAR, thoracic endovascular aortic repair.
Fig 2. One-way sensitivity analysis for 30-day mortality of thoracic
endovascular aortic repair (TEVAR), deﬁned as nonrespiratory,
nonparaplegia, nonrenal deaths, compared with open repair (OR).
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between these variable ranges that could change the su-
periority of TEVAR in net health beneﬁt (Table V).
Hypothetical worst-case scenario: 30-day mortality
of TEVAR. One-way sensitivity analysis, especially on the
operative mortality for TEVAR, showed dominance of
TEVAR over OR if its mortality rate was up to 37.5%.
With a hypothetical high mortality rate of 50%, OR would
provide improved effectiveness compared with TEVAR
with an ICER of V287,663.05 per QALY (Fig 2).
Two-way sensitivity analysis. The list of variables
tested for their joint inﬂuence on acute complicated
TBADs outcome included the systematically modelled
morbidity rates of paraplegia, stroke, and renal failure.
The same parameter ranges were used as in the one-way
sensitivity analysis. TEVAR repair emerged as the
preferred treatment option in net health beneﬁt (Table VI).
TEVAR continued to dominate OR, and the model re-
sults were not affected by varying the values of paraplegia,
stroke, renal failure, and 30-day mortality rates in the
ranges speciﬁed.
The tornado diagram displays the seven individual pa-
rameters that inﬂuence the ICER estimates the most, ar-
ranged from top to bottom in order of their importance.
As depicted in Fig 3, the tornado diagram demonstrates
that results are most sensitive to the probability of renal fail-
ure, stroke, or paraplegia after TEVAR, the costs of survival
after renal failure, stroke, or paraplegia after TEVAR, and
the costs of uneventful recovery after TEVAR.
Monte Carlo simulation. The results of the boot-
strapping are depicted in the cost-effectiveness plane
(Fig 4). The QALYs gained panel shows that 100% of
replicates fall into the right lower quadrant, indicating that
we can be 100% certain that TEVAR yields a better
outcome in QALYs at 1 year. Because all replicates lie under
the x-axis, we have 100% certainty that TEVAR is less costly
than OR. The oblique line indicates a (rather arbitrary)
societal WTP threshold of V50,000 per QALY. All repli-
cates lie under this threshold, indicating that with 100%
certainty TEVAR can be considered the preferred strategy
at a societal WTP threshold of V50,000 per QALY.Best-case and worst-case scenario. To perform the
best-case and worst-case scenario analysis, respectively, we
modelled the 10 individual parameters that inﬂuenced the
ICER estimates most, according to the tornado diagram,
to its extremes (intentionally beyond reasonable limits
published in the literature; Tables I-III).
In the base-case analysis under this scenario, TEVAR
was still the dominant therapeutic option compared with
OR. However, under these assumptions in the second-
order probabilistic sensitivity analysis, TEVAR dominated
OR in only 67.6%, TEVAR was more costly and effective
in 9.44%, and its ICER was less than or equal to the
WTP, so it was cost-effective. OR was more costly and
effective in 8.18%, but its ICER was greater than the
WTP, so TEVAR was optimal; TEVAR was more costly
and effective in 10.56%, but its ICER was greater than
the WTP, so OR was optimal. OR was more costly and
effective in 0.74%, and its ICER was less than or equal to
the WTP, so it was optimal, and OR dominated TEVAR
in 3.39% (Fig 5).
Table VI. Dominance report of two-way sensitivity
analysis
Parameter ICER
Probability paraplegia OR dominated by TEVAR
Probability stroke OR dominated by TEVAR
Probability renal failure OR dominated by TEVAR
Probability 30-day mortality OR dominated by TEVAR
ICER, Incremental cost-effectiveness ratio; OR, open repair; TEVAR,
thoracic endovascular aortic repair.
Fig 3. Tornado diagram shows the results of deterministic one-
way sensitivity analyses. Each bar represents a sensitivity variable,
and the width of a horizontal bar denotes the effect of each pa-
rameter’s uncertainty on the base-case value. The net health
beneﬁt was calculated with a threshold willingness-to-pay (WTP)
of V50,000 per quality-adjusted life year (QALY) gained. This
tornado diagram shows that the results are most sensitive to the
probability of renal failure after thoracic endovascular aortic repair
(TEVAR).
Fig 4. Incremental cost-effectiveness (ICE) scatter plot. Bootstrap
replications show the difference in costs and quality-adjusted life-
years (QALYs) on the cost-effectiveness plane between patients
undergoing thoracic endovascular aortic repair (TEVAR) or open
repair (OR) at 1 year of follow-up. Each dot represents one iter-
ation in a Monte Carlo simulation (10,000 iterations). The diag-
onal line indicates a maximum willingness-to-pay (WTP) per
QALY of V50,000 at 1 year. For clarity, only 1000 of 10,000
simulated data points are shown. The ellipse delineates the 95%
conﬁdence interval.
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The present decision analytical model found compel-
ling evidence for the following hypothesis: even when
taking into account the cost of the endograft, the cost
of conversion to OR, and the cost of reintervention and
surveillance, patients treated with TEVAR for acute
complicated TBADs dissipate less money in the ﬁrst post-
operative year than patients treated with OR, in addition
to improved TEVAR outcomes. This makes TEVAR a
dominant treatment option for acute complicated TBADs
in the ﬁrst postoperative year.
The reduction of costs caused by TEVAR in the ﬁrst
postoperative year is signiﬁcantly higher compared with
OR, especially when the treatment costs of patients who
develop paraplegia are factored in. It is well documented
that paraplegia treatment may produce costs >$100,000
in the ﬁrst year and costs w$5400 per year in perpetuity
after the ﬁfth year.35
However, whether these cost savings of TEVAR
compared with OR are durable over time remains to be evi-
denced, and we did not examine the effect of late interven-
tions after TEVAR or OR beyond the time horizon of1 year in our model. Probably, the costs of TEVAR will
be partly increased by the costs of surveillance and reinter-
vention during subsequent follow-up, but these costs may
be equated, at least partially, by the decreased paraplegia
rate of TEVAR and the costs associated with paraplegia.35
However, reintervention rates and costs for OR in the
follow-up period are not to be undervalued, especially since
as improved technologies and indication-speciﬁc endograft
design will arise, we assume the beneﬁts of TEVAR
compared with OR will increase.
The literature reporting costs and cost-effectiveness of
TEVAR vs OR is rather heterogeneous regarding the clin-
ical indication for the procedures, the included cost levels,
and follow-up times. Recently, seven studies compared the
costs of TEVAR vs OR, but to the best of our knowledge,
the present study represents the only cost-effectiveness
study based on a meta-analysis that includes total direct
1-year costs for treatment of acute complicated TBADs.
Chung et al43 analyzed traumatic thoracic aortic in-
juries and reported comparable procedure costs but higher
follow-up cost for TEVAR (US $59,170 for OR vs
$61,266 6 $428 per year for TEVAR). Tong et al33 per-
formed an economic comparison of TEVAR vs OR for
the treatment of blunt traumatic thoracic aortic injuries
with a time horizon of 1 year. In cost-effectiveness analysis,
TEVAR was the dominant therapy over OR for this disease
entity. The analysis of the 2005 to 2006 Nationwide Inpa-
tient Sample of thoracic aortic traumas by Mousa et al44
Fig 5. Incremental cost-effectiveness (ICE) scatter plot. Bootstrap
replications show the difference in costs and quality-adjusted life-
years (QALYs) on the cost-effectiveness plane between patients
undergoing thoracic endovascular aortic repair (TEVAR) or open
repair (OR) at 1 year of follow-up. Each dot represents one iter-
ation in a Monte Carlo simulation (10,000 iterations). The diag-
onal line indicates a maximum willingness-to-pay (WTP) per
QALY of V50,000 at 1 year. For clarity, only 1000 of 10,000
simulated data points are shown. The ellipse delineates the 95%
conﬁdence interval.
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compared with TEVAR. Schuster et al34 compared the
hospital costs of TEVAR and OR in patients with thoracic
aortic aneurysms. They found that the hospital costs of
TEVAR compared favorably with OR, with a difference be-
tween total costs of the two procedures of V12,543.14.
Karimi et al45 conducted a single-institution study
comparing hospital and midterm outcomes and costs for
elective TEVAR vs OR of descending thoracic aortic aneu-
rysms at 2 years. Ongoing follow-up costs associated with
complications incurred during the index surgery were not
included (eg, dialysis costs, rehabilitation costs). Karimi
et al45 revealed that mean surveillance imaging costs for
TEVAR were $1800.38 higher than for OR at 2 years;
however, the cumulative cost analysis still favored TEVAR
over OR at 2 years because of the lower initial hospitaliza-
tion costs.
Narayan et al,46 in a cost-effectiveness analysis of
TEVAR vs OR, showed that TEVAR was associated with
reduced morbidity and mortality in the short-term,
although no cost beneﬁt was associated with TEVAR in
the short-term. In the long-term, due to increased risk of
reinterventions, Narayan et al46 concluded that TEVAR
might actually prove to be a more expensive therapeutic
option compared with OR.
Finally, Azizzadeh et al47 performed an outcome anal-
ysis of TEVAR vs OR of blunt traumatic aortic injuries.
Compared with TEVAR, patients who underwent OR
had three times higher odds of a complication orin-hospital death. The mean total hospital cost of TEVAR
was not signiﬁcantly different compared with OR.
These studies largely support the results of the present
analysis identifying TEVAR as a more cost-effective thera-
peutic option than OR in a variety of thoracic aortic pathol-
ogies. Only the study by Narayan et al46 reported
seemingly contradictory results. In their cohort, the long-
term cost implications of TEVAR were postulated to be
signiﬁcant and to be largely inﬂuenced by the risk of rein-
terventions and costs of follow-up. However, when consid-
ering procedures for acute complicated TBADs, based on a
current meta-analysis7 covering only this subgroup, OR has
a very high perioperative complication rate regarding para-
plegia, stroke, and renal failure compared with TEVAR.
These complications have a great impact on future costs
during follow-up. As a result, the effect of surveillance im-
aging would be rather marginal in acute complicated
TBADs, and the associated costs would make up only a
minute part of the overall costs, which are largely domi-
nated by the long-lasting and cost-driving complications
of OR in this disease entity. In the long run, follow-up
costs and reintervention costs (which probably will not
be higher in the follow-up than already included in our
1-year analysis) might result in an ICER somewhat less
favorable for TEVAR.
Despite the minimal invasiveness of TEVAR, studies
performed to analyze and compare outcome and quality
of life after surgical and endovascular intervention showed
that TEVAR patients had no better overall quality of life
and that anxiety and depression scores were not reduced
by TEVAR compared with OR.48
This study has some limitations. A drawback of the pre-
sent study, and also of other comparative studies on costs
of (T)EVAR and OR is that none of them had a random-
ized design. This may have promoted selection bias.
The technical advances in the endovascular ﬁeld and
best medical treatment during the analyzed time period
are further possible confounders to the improved outcomes
seen with TEVAR in acute complicated TBADs compared
with OR. There is signiﬁcant literature heterogeneity in the
type of devices used, the era of the study, the patient char-
acteristics, and the management approaches.
The preoperative physical condition of the patient is a
quantity that has one of the most signiﬁcant inﬂuences of
the outcome of any surgical procedure. In patients with
TBADs, the preoperative degree of shock has a very impor-
tant effect on the outcome of OR.5 Unfortunately, in many
of the studies included in the underlaying meta-analysis,7
the incidence and degree of shock was not deﬁned in detail
or mentioned at all. Anyhow, 30% of the patients in the In-
ternational Registry of Acute Aortic Dissection who under-
went OR had signs of shock before surgery.49
In general, as with any modelling, the information
available is not always complete, and assumptions had to
be made when information was not disposable, especially
concerning the costs. The transition probabilities in our
decision tree analysis were obtained from current meta-
analyses7 and other high-quality studies.10-26
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tem perspective, and indirect costs were not included. The
reported costs therefore represent an underestimation of
the actual costs associated with both procedures.
The strength of the present analysis is that we included
ongoing follow-up costs associated with complications
incurred during the index surgery (eg, paraplegia) at 1 year.
According to the Institute for Clinical and Economic
Review Integrated Evidence Rating Table,50 our review
corresponds to category Aa (high conﬁdence of the deci-
sion analysis results and a high certainty of a moderate-
large net health beneﬁt), ranking ﬁrst on the 18-point
evidence rating scale.
CONCLUSIONS
For patients who present with acute complicated
TBADs, TEVAR decreases morbidity, mortality, and para-
plegia compared with OR. In addition, the 1-year cost is
less with TEVAR, making TEVAR the dominant therapy
over OR for acute complicated TBADs. However, the
long-term durability of the repair is unknown, and long-
term follow-up will be required to see if the cost beneﬁt
is maintained over time.
AUTHOR CONTRIBUTIONS
Conception and design: TL, JB
Analysis and interpretation: TL, JB
Data collection: TL
Writing the article: TL
Critical revision of the article: TL, JB
Final approval of the article: TL, JB
Statistical analysis: TL
Obtained funding: Not applicable
Overall responsibility: TL
REFERENCES
1. Olsson C, Thelin S, Stahle E, Ekbom A, Granath F. Thoracic aortic
aneurysm and dissection: increasing prevalence and improved outcomes
reported in a nationwide population-based study of more than 14,000
cases from 1987 to 2002. Circulation 2006;114:2611-8.
2. Tsai TT, Evangelista A, Nienaber CA, Trimarchi S, Sechtem U,
Fattori R, et al. Long-term survival in patients presenting with type A
acute aortic dissection: insights from the International Registry of Acute
Aortic Dissection (IRAD). Circulation 2006;114(1 Suppl):I350-6.
3. Tsai TT, Fattori R, Trimarchi S, Isselbacher E, Myrmel T,
Evangelista A, et al. Long-term survival in patients presenting with type
B acute aortic dissection: insights from the International Registry of
Acute Aortic Dissection. Circulation 2006;114:2226-31.
4. Elefteriades JA, Lovoulos CJ, Coady MA, Tellides G, Kopf GS,
Rizzo JA. Management of descending aortic dissection. Ann Thorac
Surg 1999;67:2002-5; discussion: 2014-9.
5. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T,
Bossone E, et al. Role and results of surgery in acute type B aortic
dissection: insights from the International Registry of Acute Aortic
Dissection (IRAD). Circulation 2006;114(1 Suppl):I357-64.
6. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspec-
tives from the International Registry of Acute Aortic Dissection
(IRAD). Eur J Vasc Endovasc Surg 2009;37:149-59.
7. Luebke T, Brunkwall J. Outcome of patients with open and endovas-
cular repair in acute complicated type B aortic dissection: a systematicreview and meta-analysis of case series and comparative studies.
J Cardiovasc Surg (Torino) 2010;51:613-32.
8. Lipscomb J. Time preference for health in cost-effectiveness analysis.
Med Care 1989;27(3 Suppl):S233-53.
9. Fujita W, Daitoku K, Taniguchi S, Fukuda I. Endovascular stent
placement for acute type-B aortic dissection with malperfusiondan
intentional surgical delay and a possible ‘bridging therapy’. Interact
Cardiovasc Thorac Surg 2009;8:266-8.
10. Amabile P, Collart F, Gariboldi V, Rollet G, Bartoli JM, Piquet P.
Surgical versus endovascular treatment of traumatic thoracic aortic
rupture. J Vasc Surg 2004;40:873-9.
11. Andrassy J, Weidenhagen R, Meimarakis G, Lauterjung L, Jauch KW,
Kopp R. Stent versus open surgery for acute and chronic traumatic
injury of the thoracic aorta: a single-center experience. J Trauma
2006;60:765-71; discussion: 771-2.
12. Broux C, Thony F, Chavanon O, Bach V, Hacini R, Sengel C, et al.
Emergency endovascular stent graft repair for acute blunt thoracic
aortic injury: a retrospective case control study. Intensive Care Med
2006;32:770-4.
13. Buz S, Zipfel B, Mulahasanovic S, Pasic M, Weng Y, Hetzer R. Con-
ventional surgical repair and endovascular treatment of acute traumatic
aortic rupture. Eur J Cardiothorac Surg 2008;33:143-9.
14. Cook J, Salerno C, Krishnadasan B, Nicholls S, Meissner M, Karmy-
Jones R. The effect of changing presentation and management on the
outcome of blunt rupture of the thoracic aorta. J Thorac Cardiovasc
Surg 2006;131:594-600.
15. Doss M, Wood JP, Balzer J, Martens S, Deschka H, Moritz A.
Emergency endovascular interventions for acute thoracic aortic
rupture: four-year follow-up. J Thorac Cardiovasc Surg 2005;129:
645-51.
16. Ott MC, Stewart TC, Lawlor DK, Gray DK, Forbes TL. Management
of blunt thoracic aortic injuries: endovascular stents versus open repair.
J Trauma 2004;56:565-70.
17. Rousseau H, Dambrin C, Marcheix B, Richeux L, Mazerolles M,
Cron C, et al. Acute traumatic aortic rupture: a comparison of surgical
and stent-graft repair. J Thorac Cardiovasc Surg 2005;129:1050-5.
18. Kasirajan K, Heffernan D, Langsfeld M. Acute thoracic aortic trauma: a
comparison of endoluminal stent grafts with open repair and nonop-
erative management. Ann Vasc Surg 2003;17:589-95.
19. Kokotsakis J, Kaskarelis I, Misthos P, Athanasiou T, Kanakakis K,
Athanasiou C, et al. Endovascular versus open repair for blunt thoracic
aortic injury: short-term results. Ann Thorac Surg 2007;84:1965-70.
20. Lebl DR, Dicker RA, Spain DA, Brundage SI. Dramatic shift in the
primary management of traumatic thoracic aortic rupture. Arch Surg
2006;141:177-80.
21. McPhee JT, Asham EH, Rohrer MJ, Singh MJ, Wong G, Vorhies RW,
et al. The midterm results of stent graft treatment of thoracic aortic
injuries. J Surg Res 2007;138:181-8.
22. Midgley PI, Mackenzie KS, Corriveau MM, Obrand DI, Abraham CZ,
Fata P, et al. Blunt thoracic aortic injury: a single institution comparison
of open and endovascular management. J Vasc Surg 2007;46:662-8.
23. Riesenman PJ, Farber MA, Rich PB, Sheridan BC, Mendes RR,
Marston WA, et al. Outcomes of surgical and endovascular treatment
of acute traumatic thoracic aortic injury. J Vasc Surg 2007;46:934-40.
24. Stampﬂ P, Greitbauer M, Zimpfer D, Fleck T, Schoder M, Lammer J,
et al. Mid-term results of conservative, conventional and endovascular
treatment for acute traumatic aortic lesions. Eur J Vasc Endovasc Surg
2006;31:475-80.
25. Yamane BH, Tefera G, Hoch JR, Turnipseed WD, Acher CW. Blunt
thoracic aortic injury: open or stent graft repair? Surgery 2008;144:
575-80; discussion: 580-2.
26. Demetriades D, Velmahos GC, Scalea TM, Jurkovich GJ, Karmy-
Jones R, Teixeira PG, et al. Operative repair or endovascular stent graft
in blunt traumatic thoracic aortic injuries: results of an American As-
sociation for the Surgery of Trauma Multicenter Study. J Trauma
2008;64:561-70; discussion: 570-1.
27. Greenberg RK, Lu Q, Roselli EE, Svensson LG, Moon MC,
Hernandez AV, et al. Contemporary analysis of descending thoracic
and thoracoabdominal aneurysm repair: a comparison of endovascular
and open techniques. Circulation 2008;118:808-17.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 5 Luebke and Brunkwall 125528. Cheng D, Martin J, Shennib H, Dunning J, Muneretto C, Schueler S,
et al. Endovascular aortic repair versus open surgical repair for
descending thoracic aortic disease a systematic review and meta-analysis
of comparative studies. J Am Coll Cardiol 2010;55:986-1001.
29. Krause JS, Sternberg M, Lottes S, Maides J. Mortality after spinal cord
injury: an 11-year prospective study. Arch Phys Med Rehabil 1997;78:
815-21.
30. Brown CV, Dubose JJ, Hadjizacharia P, Yanar H, Salim A, Inaba K,
et al. Natural history and outcomes of renal failure after trauma. J Am
Coll Surg 2008;206:426-31.
31. Dunham MB, Zygun D, Petrasek P, Kortbeek JB, Karmy-Jones R,
Moore RD. Endovascular stent grafts for acute blunt aortic injury.
J Trauma 2004;56:1173-8.
32. Bent CL, Matson MB, Sobeh M, Renfrew I, Uppal R, Walsh M, et al.
Endovascular management of acute blunt traumatic thoracic aortic
injury: a single center experience. J Vasc Surg 2007;46:920-7.
33. Tong MZ, Koka P, Forbes TL. Economic evaluation of open vs
endovascular repair of blunt traumatic thoracic aortic injuries. J Vasc
Surg 2010;52:31-8.e3.
34. Schuster I, Dorfmeister M, Scheuter-Mlaker S, Gottardi R,
Hoebartner M, Roedler S, et al. Endovascular and conventional
treatment of thoracic aortic aneurysms: a comparison of costs. Ann
Thorac Surg 2009;87:1801-5.
35. Dryden DM, Saunders LD, Jacobs P, Schopﬂocher DP, Rowe BH,
May LA, et al. Direct health care costs after traumatic spinal cord
injury. J Trauma 2005;59:443-9.
36. Dick F, Hinder D, Immer FF, Savolainen H, Do DD, Carrel TP, et al.
Thoracic endovascular aortic repair: impact of urgency on outcome and
quality of life. Eur J Cardiothorac Surg 2009;35:96-103.
37. Dick F, Hirzel C, Immer FF, Hinder D, Dai-Do D, Carrel TP, et al.
Quality of life after acute type B dissection in the era of thoracic
endovascular aortic repair. Vasa 2010;39:219-28.
38. Patel HJ. Outcome and quality of life after surgical and endovascular
treatment of descending aortic lesions. Invited commentary. Ann
Thorac Surg 2008;85:1612-3.
39. Di Luozzo G, Shirali AS, Varghese R, Lin HM, Weiss AJ, Bischoff MS,
et al. Quality of life and survival of septuagenarians and octogenarians
after repair of descending and thoracoabdominal aortic aneurysms.
J Thorac Cardiovasc Surg 2013;145:378-84.40. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-
term outcome after stroke: evaluating health-related quality of life using
utility measurements. Stroke 2006;37:193-8.
41. Duncan PW, Lai SM, Keighley J. Deﬁning post-stroke recovery: im-
plications for design and interpretation of drug trials. Neuropharma-
cology 2000;39:835-41.
42. Burstrom K, Johannesson M, Diderichsen F. Swedish population
health-related quality of life results using the EQ-5D. Qual Life Res
2001;10:621-35.
43. Chung J, Owen R, Turnbull R, Chyczij H, Winkelaar G, Gibney N.
Endovascular repair in traumatic thoracic aortic injuries: comparison
with open surgical repair. J Vasc Interv Radiol 2008;19:479-86.
44. Mousa AY, Dombrovskiy VY, Haser PB, Graham AM, Vogel TR.
Thoracic aortic trauma: outcomes and hospital resource utilization after
endovascular and open repair. Vascular 2010;18:250-5.
45. Karimi A, Walker KL, Martin TD, Hess PJ, Klodell CT, Feezor RJ,
et al. Midterm cost and effectiveness of thoracic endovascular aortic
repair versus open repair. Ann Thorac Surg 2012;93:473-9.
46. Narayan P, Wong A, Davies I, Angelini GD, Bryan AJ, Wilde P, et al.
Thoracic endovascular repair versus open surgical repairdwhich is the
more cost-effective intervention for descending thoracic aortic pa-
thologies? Eur J Cardiothorac Surg 2011;40:869-74.
47. Azizzadeh A, Charlton-Ouw KM, Chen Z, Rahbar MH, Estrera AL,
Amer H, et al. An outcome analysis of endovascular versus open repair
of blunt traumatic aortic injuries. J Vasc Surg 2013;57:108-14; dis-
cussion: 115.
48. Okamoto Y, Motomura N, Murashima S, Takamoto S. Anxiety and
depression after thoracic aortic surgery or coronary artery bypass. Asian
Cardiovasc Thorac Ann 2013;21:22-30.
49. Trimarchi S, Tolenaar JL, Tsai TT, Froehlich J, Pegorer M,
Upchurch GR, et al. Inﬂuence of clinical presentation on the outcome
of acute B aortic dissection: evidences from IRAD. J Cardiovasc Surg
(Torino) 2012;53:161-8.
50. Ollendorf DA, Pearson SD. An integrated evidence rating to frame
comparative effectiveness assessments for decision makers. Med Care
2010;48(6 Suppl):S145-52.Submitted Sep 18, 2013; accepted Nov 26, 2013.
